Literature DB >> 8135868

Expression of monomorphic and polymorphic N-acetyltransferases in human colon.

K F Ilett1, D M Ingram, D S Carpenter, C H Teitel, N P Lang, F F Kadlubar, R F Minchin.   

Abstract

The metabolism of sulfamethazine (SMZ) and p-aminobenzoic acid (PABA) by N-acetyltransferase (NAT) was measured in human colorectal cytosols from 12 slow and 11 rapid acetylators whose genotype was determined independently by a specific polymerase chain reaction. SMZ metabolism was significantly greater in the rapid than in the slow phenotype (192 +/- 22 versus 94 +/- 11 pmol N-acetylsulfamethazine/min/mg protein), while PABA metabolism was similar in both phenotypes (23.7 +/- 4.4 versus 23.0 +/- 3.9 nmol N-acetyl-p-aminobenzoic acid/min/mg protein). Both monomorphic and polymorphic NAT mRNAs were detected by the polymerase chain reaction in the colorectal mucosa of most samples. The finding that polymorphic NAT is expressed in a phenotype-dependent manner in colorectal mucosa indicates that this tissue has the capacity to participate in local bioactivation of dietary and environmental aryl- or heterocyclic amine carcinogens and may explain, in part, the phenotype-dependent occurrence of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8135868     DOI: 10.1016/0006-2952(94)90493-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

1.  N-Acetyltransferase polymorphism and human cancer risk.

Authors:  X Yang; T Takeshita; K Morimoto
Journal:  Environ Health Prev Med       Date:  2000-01       Impact factor: 3.674

2.  N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions.

Authors:  A L Hubbard; D J Harrison; C Moyes; A H Wyllie; C Cunningham; E Mannion; C A Smith
Journal:  Gut       Date:  1997-08       Impact factor: 23.059

3.  Expression of arylamine N-acetyltransferase in human intestine.

Authors:  D Hickman; J Pope; S D Patil; G Fakis; V Smelt; L A Stanley; M Payton; J D Unadkat; E Sim
Journal:  Gut       Date:  1998-03       Impact factor: 23.059

4.  Acetylation of arylamines by the placenta.

Authors:  V A Smelt; H J Mardon; C W Redman; E Sim
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Oct-Dec       Impact factor: 2.441

5.  Genomic organization of human arylamine N-acetyltransferase Type I reveals alternative promoters that generate different 5'-UTR splice variants with altered translational activities.

Authors:  Neville J Butcher; Ajanthy Arulpragasam; Hui Li Goh; Tamara Davey; Rodney F Minchin
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

6.  Modification by N-acetyltransferase 1 genotype on the association between dietary heterocyclic amines and colon cancer in a multiethnic study.

Authors:  Lesley M Butler; Robert C Millikan; Rashmi Sinha; Temitope O Keku; Scott Winkel; Brent Harlan; Allison Eaton; Marilie D Gammon; Robert S Sandler
Journal:  Mutat Res       Date:  2007-10-13       Impact factor: 2.433

7.  Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2.

Authors:  Verónica Ramírez-Alcántara; Marshall H Montrose
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-17       Impact factor: 4.052

8.  Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements.

Authors:  Anwar Husain; Xiaoyan Zhang; Mark A Doll; J Christopher States; David F Barker; David W Hein
Journal:  Drug Metab Dispos       Date:  2007-06-25       Impact factor: 3.922

Review 9.  N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.

Authors:  D W Hein
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

10.  Meta-analysis of cytochrome P-450 2C9 polymorphism and colorectal cancer risk.

Authors:  Shuo Liang; Jinsong Hu; Jingsong Hu; Weijun Cao; Sanjun Cai
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.